C. Visseren-Grul - Medical Oncology Department, Eli Lilly and Company

基本信息

浏览量：65

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 115 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

RELAY: Final Overall Survival for Erlotinib + Ramucirumab or Placebo in Untreated, EGFR-Mutated Metastatic NSCLC

Kazuhiko Nakagawa,Edward B. Garon,Takashi Seto,Makoto Nishio,Santiago Ponce Aix,Luis Paz-Ares,Chao-Hua Chiu,Keunchil Park,Silvia Novello,Ernest Nadal,Kazumi Nishino,Kiyotaka Yoh,Jin-Yuan Shih,Jeannie YK. Chik,Denis Moro-Sibilot,Tarun Puri, Sunoj Chacko Varughese,Bente Frimodt-Moller,Carla Visseren-Grul,Martin Reck

Journal of Thoracic Oncology (2024)

引用0浏览0WOS引用

RELAY, Erlotinib Plus Ramucirumab in Untreated, EGFR-Mutated, Metastatic NSCLC: Outcomes by EGFR Exon 19 Deletion Variants

Kazumi Nishino,Jin-Yuan Shih,Kazuhiko Nakagawa,Martin Reck,Edward B. Garon,Michelle Carlsen,Tomoko Matsui,Carla Visseren-Grul,Ernest Nadal

JTO CLINICAL AND RESEARCH REPORTS（2024）

引用0浏览0WOS引用

Table S4 from RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

Kazuhiko Nakagawa,Ernest Nadal,Edward B. Garon,Makoto Nishio,Takashi Seto,Nobuyuki Yamamoto,Keunchil Park,Jin-Yuan Shih,Luis Paz-Ares,Bente Frimodt-Moller,Annamaria H. Zimmermann,Sameera Wijayawardana,Carla Visseren-Grul,Martin Reck

openalex（2023）

引用0浏览0引用

Table S3 from RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

openalex（2023）

引用0浏览0引用

Clinical Outcomes of Ramucirumab Plus Docetaxel in the Treatment of Patients with Non-Small Cell Lung Cancer after Immunotherapy: a Systematic Literature Review

Edward B. Garon,Carla Visseren-Grul,Maria Teresa Rizzo,Tarun Puri, Suresh Chenji,Martin Reck

Frontiers in Oncology (2023)

引用4浏览0WOS引用

Figure S7 from RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

openalex（2023）

引用0浏览0引用

Impact of Ramucirumab Plus Erlotinib on Circulating Cell-Free DNA from Patients with Untreated Metastatic Non-Small Cell Lung Cancer with EGFR-activating Mutations (RELAY Phase 3 Randomized Study)

Kazuto Nishio,Kazuko Sakai,Makoto Nishio,Takashi Seto,Carla Visseren-Grul,Michelle Carlsen,Tomoko Matsui,Sotaro Enatsu,Kazuhiko Nakagawa

Translational Lung Cancer Research（2023）

引用5浏览0WOS引用

Table S5 from RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non–Small Cell Lung Cancer

Kazuhiko Nakagawa,Ernest Nadal,Edward B. Garon,Makoto Nishio,Takashi Seto,Nobuyuki Yamamoto,Keunchil Park,Jin‐Yuan Shih,Luis Paz‐Ares,Bente Frimodt‐Moller,Annamaria H. Zimmermann,Sameera R. Wijayawardana,Carla Visseren‐Grul,Martin Reck

openalex（2023）

引用0浏览0引用

RELAY, Ramucirumab Plus Erlotinib (RAM+ERL) in Untreated Metastatic EGFR-Mutant NSCLC (EGFR+ NSCLC): Association Between TP53 Status and Clinical Outcome

Makoto Nishio,Luis Paz-Ares,Martin Reck,Kazuhiko Nakagawa,Edward B. Garon,Sanjay Popat,Matteo Ceccarelli,Hillary T. Graham,Carla Visseren-Grul,Silvia Novello

Clinical Lung Cancer（2023）

引用12浏览0WOS引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn